Michael E. Mendelsohn, MD is an internationally recognized cardiovascular physician-scientist with broad experience in academia and industry. Dr. Mendelsohn received his BA in Chemistry and English from Amherst College and his MD from Harvard Medical School. He trained in both Internal and CV Medicine at Brigham and Women's Hospital and spent 25 years as an academic physician-scientist in Boston, first at HMS, and then at Tufts Medical Center, where in 1998 he created the Molecular Cardiology Research Institute, a basic and translational CV Research Department. In 2008, he became the first CSO at Tufts, and in 2010, he moved to Merck & Co. to be Global Head of Cardiovascular Diseases, with responsibilities for scientific strategy, drug discovery, clinical research, and business development. He is currently Chairman of Cardurion Pharmaceuticals, which he founded in 2016, a clinical-stage biotechnology company focused on discovery and development of novel cardiovascular therapeutics.